SCHEMBL25759435

SCHEMBL25759435

CCOC(O)Cc1ccc(N)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
NHERF1 O14745 1/20 0.41
MAPT P10636 9/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
TP53 P04637 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDH1 O75874 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25759506 0.90 GAA (0.43) GAAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL25759512 0.89 MAPT (0.47) GAAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL25754833 0.82 PKM (0.54) GAAPKMNHERF1MAPTMEN1
SCHEMBL23846511 0.79 NHERF1 (0.49) GAAPKMNHERF1MAPTSMN1; SMN2
SCHEMBL17980891 0.71 MAPT (0.60) GAAPKMMAPTSMN1; SMN2MEN1
SCHEMBL25754797 0.71 GAA (0.50) GAAPKMMAPTSMN1; SMN2MEN1
SCHEMBL25754837 0.70 MAPT (0.58) GAAMAPTMEN1KMT2ALMNA
SCHEMBL23846466 0.70 LMNA (0.47) GAAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL23847021 0.69 PKM (0.56) GAAPKMMAPTSMN1; SMN2MEN1
SCHEMBL25759510 0.68 MAPT (0.47) GAAMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 GAA 1667/4885PKM 2001/4885NHERF1 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.